VRDN vs. RDNT, BTSG, SHC, CON, PRVA, SGRY, WGS, VCYT, ADUS, and PACS
Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), Surgery Partners (SGRY), GeneDx (WGS), Veracyte (VCYT), Addus HomeCare (ADUS), and PACS Group (PACS). These companies are all part of the "healthcare" industry.
Viridian Therapeutics vs. Its Competitors
RadNet (NASDAQ:RDNT) and Viridian Therapeutics (NASDAQ:VRDN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.
In the previous week, RadNet had 6 more articles in the media than Viridian Therapeutics. MarketBeat recorded 6 mentions for RadNet and 0 mentions for Viridian Therapeutics. RadNet's average media sentiment score of 0.79 beat Viridian Therapeutics' score of 0.00 indicating that RadNet is being referred to more favorably in the media.
77.9% of RadNet shares are owned by institutional investors. 5.6% of RadNet shares are owned by insiders. Comparatively, 1.6% of Viridian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.
RadNet has a net margin of -1.73% compared to Viridian Therapeutics' net margin of -102,092.39%. RadNet's return on equity of 1.41% beat Viridian Therapeutics' return on equity.
RadNet has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.
RadNet presently has a consensus target price of $69.60, suggesting a potential upside of 23.93%. Viridian Therapeutics has a consensus target price of $37.56, suggesting a potential upside of 140.97%. Given Viridian Therapeutics' higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than RadNet.
Summary
RadNet beats Viridian Therapeutics on 13 of the 17 factors compared between the two stocks.
Get Viridian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viridian Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VRDN) was last updated on 7/3/2025 by MarketBeat.com Staff
